Peripheral Blood Stem Cell Transplantation in a Young Patient with IgA Multiple Myeloma

• Published in: Japanese Journal of National Medical Services Vol. 50; no. 10; pp. 721 - 725
• Main Authors: IHARA Akihiro, FURUBAYASHI Takayasu, NAKAO Hirohisa, TOMINAGA Nobuhiko, ISHIKAWA Katsunori, HADA Yoshihiro, NOZAKI Tadaharu
• Format: Journal Article
• Language: Japanese
• Published: Japanese Society of National Medical Services 1996; 一般社団法人 国立医療学会
• Subjects: IgA myeloma; IgA骨髄腫; PBSCT; young patient; 末梢血幹細胞移植; 若年者
• ISSN: 0021-1699; 1884-8729
• DOI: 10.11261/iryo1946.50.721

Dose intensity chemotherapy with auto-peripheral blood stem cell support (PBSCT) is useful therapy for patients with multiple myeloma who show high serum levels of β2 microglobin. We treated a 51-year-old-male with IgA-κtype multiple myeloma with high-dose melphalan (200mg/body) and total body irradiation (total 12 Gray) supported by autologous peripheral blood stem cells. He achieved complete remission one month after PBSCT and complete remission lasted with-out any further therapy for six month. However he relapsed and died of myeloma cell infiltration one year after relapsing. Controlled trials should clarify more definitively the role of PBSCT for specific groups of patients with multiple myeloma. 末梢血幹細胞(PBSC)の支持のもとに施行する超大量化学療法は多発性骨髄腫のよい治療法と考えられる. 我々は予後不良と考えられる51歳の若年者IgA-κ型骨髄腫にメルファラン大量(200mg/body)と全身放射線照射(合計12グレイ)のコンディショニングで末梢血幹細胞移植(PBSCT)を施行した. PBSCT 1カ月後に完全寛解となり, その後無治療で6カ月完全寛解が持続したが, 再発から6カ月後に骨髄腫細胞の浸潤で死亡した. 骨髄腫でのPBSCTによる治療の意義を明らかにするためコントロールスタディが必要と考えられる.